With 0.54 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.49 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $1.83 whereas the lowest price it dropped to was $1.56. The 52-week range on JUNS shows that it touched its highest point at $19.51 and its lowest point at $0.51 during that stretch. It currently has a 1-year price target of $30.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of JUNS was down-trending over the past week, with a drop of -29.26%, but this was up by 73.02% over a month. Three-month performance surged to 129.23% while six-month performance fell -70.00%. A look at the trailing 12-month EPS for JUNS yields -0.10 with Next year EPS estimates of 0.11. For the next quarter, that number is -0.07. This implies an EPS growth rate of -212.50% for this year and 144.00% for next year.
Float and Shares Shorts:
At present, 33.10 million JUNS shares are outstanding with a float of 13.88 million shares on hand for trading. On 2025-06-13, short shares totaled 0.28 million, which was 86.0 higher than short shares on 1747267200. In addition to Mr. Christer Rosen as the firm’s Co-Founder, CEO & Chairman of the Board, Ms. Alison D. Silva MA, MS serves as its President, Chief Business Officer & Director.
Institutional Ownership:
Through their ownership of 0.01171 of JUNS’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, JUNS reported revenue of $0.0 and operating income of -$1538003.0. The EBITDA in the recently reported quarter was -$1527638.0 and diluted EPS was -$0.05.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With JUNS analysts setting a high price target of 30.0 and a low target of 30.0, the average target price over the next 12 months is 30.0. Based on these targets, JUNS could surge 1751.85% to reach the target high and rise by 1751.85% to reach the target low. Reaching the average price target will result in a growth of 1751.85% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.06 being high and -$0.06 being low. For JUNS, this leads to a yearly average estimate of -$0.06.
